These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33929488)

  • 1. SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort.
    van Kempen ZLE; Strijbis EMM; Al MMCT; Steenhuis M; Uitdehaag BMJ; Rispens T; Killestein J
    JAMA Neurol; 2021 Jul; 78(7):880-882. PubMed ID: 33929488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.
    Zabalza A; Arrambide G; Tagliani P; Cárdenas-Robledo S; Otero-Romero S; Esperalba J; Fernandez-Naval C; Trocoli Campuzano J; Martínez Gallo M; Castillo M; Bonastre M; Resina Sallés M; Beltran J; Carbonell-Mirabent P; Rodríguez-Barranco M; López-Maza S; Melgarejo Otálora PJ; Ruiz-Ortiz M; Pappolla A; Rodríguez Acevedo B; Midaglia L; Vidal-Jordana A; Cobo-Calvo A; Tur C; Galán I; Castilló J; Río J; Espejo C; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encephalopathy associated with COVID-19 in a patient with multiple sclerosis.
    Naser Moghadasi A
    J Neurovirol; 2020 Dec; 26(6):973-975. PubMed ID: 33118141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
    Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
    Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
    Bollo L; Guerra T; Bavaro DF; Monno L; Saracino A; Angarano G; Paolicelli D; Trojano M; Iaffaldano P
    J Neurol Sci; 2020 Sep; 416():117011. PubMed ID: 32650143
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
    Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
    Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
    Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study.
    Bigaut K; Kremer L; Fabacher T; Lanotte L; Fleury MC; Collongues N; de Seze J
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34321333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report.
    Lucchini M; Bianco A; Del Giacomo P; De Fino C; Nociti V; Mirabella M
    Mult Scler Relat Disord; 2020 Sep; 44():102323. PubMed ID: 32593961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.
    Flores-Gonzalez RE; Hernandez J; Tornes L; Rammohan K; Delgado S
    Mult Scler Relat Disord; 2021 Apr; 49():102777. PubMed ID: 33508573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.
    Mantero V; Abate L; Balgera R; Basilico P; Salmaggi A; Cordano C
    Mult Scler Relat Disord; 2020 Nov; 46():102453. PubMed ID: 32835900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
    Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
    Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit.
    Sepúlveda M; Llufriu S; Martínez-Hernández E; Català M; Artola M; Hernando A; Montejo C; Pulido-Valdeolivas I; Martínez-Heras E; Guasp M; Solana E; Llansó L; Escudero D; Aldea M; Prats C; Graus F; Blanco Y; Saiz A
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33504634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 in multiple sclerosis: The Dutch experience.
    Loonstra FC; Hoitsma E; van Kempen ZL; Killestein J; Mostert JP
    Mult Scler; 2020 Sep; 26(10):1256-1260. PubMed ID: 32662742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a population-based study.
    Schaffner A; Risch L; Weber M; Thiel S; Jüngert K; Pichler M; Wohlwend N; Lung T; Ritzler M; Hillmann D; Copeland S; Renz H; Paprotny M; Risch M
    Clin Chem Lab Med; 2020 Nov; 59(2):e49-e51. PubMed ID: 33554502
    [No Abstract]   [Full Text] [Related]  

  • 16. Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays.
    Kahre E; Galow L; Unrath M; Haag L; Blankenburg J; Dalpke AH; Lück C; Berner R; Armann JP
    Sci Rep; 2021 Jul; 11(1):14893. PubMed ID: 34290329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy.
    Kastritis E; Terpos E; Evangelakou Z; Theodorakakou F; Fotiou D; Manola MS; Gianniou DD; Bagratuni T; Kanellias N; Migkou M; Gavriatopoulou M; Trougakos IP; Dimopoulos MA
    Am J Hematol; 2022 Jan; 97(1):E27-E31. PubMed ID: 34778995
    [No Abstract]   [Full Text] [Related]  

  • 20. Seroprevalence of SARS-CoV-2 in Pakistan: an update on epidemiological trends.
    Waqar M; Wahid B; Idrees M; Ali M; Rehman Z
    Z Naturforsch C J Biosci; 2021 Sep; 76(9-10):425-429. PubMed ID: 34161693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.